From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade names Seysara
CAS Number
PubChem CID
Chemical and physical data
Formula C24H29N3O8
Molar mass 487.51 g·mol−1
3D model (JSmol)

Sarecycline (trade name Seysara; development code WC-3035) is a tetracycline-derived antibiotic. In the United States, it was approved by the FDA in October 2018 for the treatment of moderate to severe acne vulgaris.[1]

Paratek Pharmaceuticals, Inc. licensed the US rights to sarecycline for the treatment of acne in the United States to Actavis, a subsidiary of Allergan, while retaining rights in the rest of the world.[2]

Allergan initiated a Phase 3 study in December 2014 evaluating the efficacy and safety of sarecycline tablets 1.5 mg/kg per day taken orally for 12 weeks versus placebo in the treatment of acne vulgaris.[3] Two phase 3 randomized, multi-center, double-blind, placebo-controlled studies evaluating the efficacy and safety of sarecycline in moderate to severe acne reported positive results on 27 March 2017.[4]


  1. ^ "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.
  2. ^
  3. ^ "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne - Full Text View -".
  4. ^ "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". Retrieved 16 May 2017.

External links[edit]